Valuation: OLIPASS Corporation

Market Cap 26.53B 18.78M 16.28M 15.24M 13.9M 26.16M 1.79B 26.6M 179M 70M 897M 70.52M 68.98M 2.99B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.4M 12.48M 11.68M 10.66M 20.05M 1.37B 20.39M 137M 53.65M 687M 54.05M 52.87M 2.29B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-92.46% 9.5M
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-1.75%+33.85%+17.09%+489.30% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
+0.40%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-3.06%-7.95%+37.80%+139.54% 13.12B
Average -1.19%+347.05%+53.89%+174.51% 26.77B
Weighted average by Cap. -0.40%+349.15%+56.25%+164.97%

Financials

2021 2022
Net sales 852M 603K 523K 489K 446K 840K 57.51M 854K 5.74M 2.25M 28.79M 2.26M 2.21M 96.04M 2.3B 1.63M 1.41M 1.32M 1.2M 2.26M 155M 2.3M 15.46M 6.06M 77.6M 6.1M 5.97M 259M
Net income -25.13B -17.79M -15.42M -14.44M -13.17M -24.79M -1.7B -25.2M -169M -66.32M -849M -66.81M -65.35M -2.83B -24.17B -17.11M -14.83M -13.88M -12.66M -23.83M -1.63B -24.23M -163M -63.77M -817M -64.24M -62.84M -2.72B
Net Debt -18.29B -12.95M -11.22M -10.5M -9.58M -18.04M -1.23B -18.34M -123M -48.26M -618M -48.62M -47.56M -2.06B -6.2B -4.39M -3.8M -3.56M -3.25M -6.11M -418M -6.21M -41.72M -16.35M -209M -16.47M -16.11M -698M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock